Xarelto Acute Coronary Syndromes Claim Faces Data Quality Hurdle
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA will ask its cardio-renal advisory committee whether missing data in J&J/Bayer’s ATLAS study affects the interpretability of rivaroxaban’s demonstrated efficacy in acute coronary syndromes. The panel also will be asked whether the agency should pre-specify clinical trial standards for data quality to reduce the problems associated with missing data in CV outcomes studies.